Macrophage Activation Syndrome (MAS) Market Outlook, Epidemiology, and Forecast 2020 to 2034 | DelveInsight
DelveInsight's Macrophage Activation Syndrome Market Insights report delivers an in-depth analysis of prevailing treatment approaches, emerging therapeutic candidates, individual therapy market shares, and both historical and projected market size spanning 2020 to 2034. The analysis covers key geographies including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2024, the macrophage activation syndrome treatment market across the leading 6MM regions (the United States, EU4, and the United Kingdom) was valued at approximately USD 110 million.
The United States dominated the landscape, representing roughly 91% of the total 6MM market value in 2024.
An estimated 22,000 diagnosed prevalent MAS cases were recorded across the 6MM in 2024, with this figure anticipated to climb steadily through the forecast period (2025–2034). The projected growth is largely attributed to rising rates of autoimmune, autoinflammatory, and infectious diseases where MAS presents as a secondary complication.
Several prominent pharmaceutical companies — including Electra Therapeutics, TJ Biopharma, AB2 Bio, Novartis, Deepcure, and others — are actively advancing novel MAS therapeutics poised to enter the market in the coming years.
Key pipeline candidates under clinical evaluation include ELA026, Plonmarlimab (TJM2/TJ003234), Tadekinig alfa (r-hIL-18BP), MAS825, and additional investigational agents.
Based on current projections, tadekinig alfa (r-hIL-18BP) is expected to launch in the US market by 2026.
Discover the new macrophage activation syndrome treatment @ Macrophage Activation Syndrome Treatment Market - https://www.delveinsight.com/report-store/macrophage-activation-syndrome-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Rising MAS Prevalence: The diagnosed MAS patient population continues to expand. Across the 6MM, approximately 22,000 cases were identified in 2024, and this number is forecast to grow through 2034.
Improved Diagnostics and Early Detection: Given the overlapping clinical presentation of MAS with other inflammatory and infectious conditions, there is growing emphasis on enhanced diagnostic awareness, novel biomarker identification, and standardized early detection protocols. Timely diagnosis facilitates prompt treatment, improving survival rates and expanding the treatable patient population.
Introduction of Novel Targeted Therapies: The MAS therapeutic landscape is expected to undergo significant transformation with the anticipated launch of emerging agents such as ELA026 (Electra Therapeutics), Plonmarlimab (TJ Biopharma), Tadekinig alfa (AB2 Bio), MAS825 (Novartis), and others.
Progress in Targeted Immunomodulatory Drug Development: Innovative drug classes — including JAK inhibitors, anti-interferon antibodies, and IL-1/IL-6 pathway blockers — present opportunities for more precise, differentiated therapeutic approaches.
Macrophage activation syndrome is a potentially fatal hyperinflammatory condition that demands swift identification and immediate therapeutic intervention.
Early administration of immunomodulatory treatments has demonstrated significant mortality reduction in both pediatric and adult patient populations.
Glucocorticoids continue to serve as the foundation of MAS management, though supplementary immunosuppressive and biologic agents are being utilized with growing frequency.
Systemic corticosteroids, frequently administered alongside cyclosporine A, remain the standard first-line treatment regimen.
For treatment-refractory cases, cytokine-directed biologics (such as anakinra) are increasingly favored over traditional cytotoxic therapies like etoposide.
The heterogeneous clinical manifestation of MAS means the condition may be significantly underdiagnosed, particularly among pediatric patients with underlying infectious or inflammatory disorders.
GAMIFANT (emapalumab) stands as the first and only FDA-approved monotherapy indicated for both adult and pediatric patients (including neonates) with HLH/MAS linked to known or suspected Still's disease — encompassing systemic juvenile idiopathic arthritis (sJIA) — in those who demonstrate inadequate response to or intolerance of glucocorticoids, or who experience recurrent MAS episodes. This regulatory milestone represents the introduction of the first targeted therapy for this critical hyperinflammatory disorder.
Despite these advancements, no therapies have been approved specifically for MAS as a standalone indication, highlighting a considerable unmet clinical need. This gap presents a significant opportunity for investigational targeted agents — including Tadekinig alfa, ELA026, Plonmarlimab, and MAS825 — to shape future treatment paradigms, influence regulatory frameworks, and potentially establish first-in-class therapies specifically for MAS.
Several investigational MAS therapies are currently progressing through clinical development, including ELA026 (Electra Therapeutics), Plonmarlimab (TJ Biopharma), Tadekinig alfa (AB2 Bio), MAS825 (Novartis), and additional candidates.
ELA026 from Electra Therapeutics is a first-in-class monoclonal antibody engineered to target Signal Regulatory Proteins (SIRPs) found on the surface of myeloid cells and T lymphocytes. By selectively depleting disease-driving immune cells, this novel mechanism holds therapeutic promise across multiple conditions.
Tadekinig alfa, developed by AB2 Bio, is a novel recombinant human interleukin-18 binding protein (IL-18BP) designed to neutralize IL-18 — a pivotal pro-inflammatory cytokine. Under normal physiological conditions, naturally occurring IL-18BP maintains free IL-18 at undetectable systemic levels. Tadekinig alfa is currently undergoing evaluation in a Phase III clinical trial.
In January 2025, AB2 Bio entered into an option and licensing agreement with Nippon Shinyaku covering US territories. Under the terms of this partnership, Nippon Shinyaku holds exclusive US commercialization rights for Tadekinig alfa in its primary indication — monogenic IL-18–driven hyperinflammatory syndrome associated with NLRC4 mutations and XIAP deficiency — spanning the US, Guam, Puerto Rico, and the US Virgin Islands. AB2 Bio retains rights for all other indications within these territories and for all indications in markets outside the US. The company continues to advance preparations for filing a US Biologics License Application (BLA) for Tadekinig alfa in this indication.
The expected market entry of these novel therapies is poised to reshape the MAS treatment landscape significantly. As these advanced candidates mature through development and secure regulatory approvals, they are expected to redefine standards of care while creating new avenues for clinical innovation and market expansion.
Discover more about the macrophage activation syndrome drugs @ Macrophage Activation Syndrome Drugs Market - https://www.delveinsight.com/report-store/macrophage-activation-syndrome-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Regional Competitive Landscape
Recent Macrophage Activation Syndrome Market Developments
In October 2025, ELA026 was granted Breakthrough Therapy Designation (BTD) by the US FDA and received Priority Medicines (PRIME) designation from the European Medicines Agency for secondary HLH (sHLH).
In October 2025, Electra Therapeutics completed an oversubscribed USD 183 million Series C financing round. The round was co-led by Nextech and EQT Life Sciences, with participation from new investors Sanofi, HBM Healthcare Investments, and Mubadala Capital, alongside existing backers including OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital, and RA Capital Management.
Macrophage activation syndrome (MAS) is a rare, severe, and potentially fatal hyperinflammatory condition defined by uncontrolled activation and expansion of macrophages and T lymphocytes, culminating in a cytokine storm. It most commonly arises in association with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), though it can also develop secondary to infections, malignancies, or other autoimmune and autoinflammatory conditions. MAS triggers excessive immune-mediated tissue destruction, presenting with hallmark clinical features including persistent high-grade fever, hepatosplenomegaly, cytopenias, hepatic dysfunction, coagulopathy, and markedly elevated inflammatory biomarkers — notably ferritin. Rapid clinical recognition coupled with aggressive immunosuppressive intervention is essential, as untreated MAS can swiftly progress to multi-organ failure.
The epidemiology section of the report offers detailed historical and projected insights into the MAS patient population across key markets. MAS affects both pediatric and adult demographics — occurring most commonly in children with sJIA and Kawasaki disease (KD), while adult cases are more frequently observed in AOSD, systemic lupus erythematosus (SLE), and secondary triggers such as infections or malignancies.
The report provides comprehensive epidemiological analysis for the 2020–2034 study period across leading markets, segmented by:
Parameter | Details |
Study Period | 2020–2034 |
Geographic Coverage | 7MM (United States, EU4 — Germany, France, Italy, Spain — United Kingdom, and Japan) |
MAS Market CAGR (6MM) | 24.7% |
MAS Market Size in 2024 (6MM) | USD 110 Million |
Key Companies | Electra Therapeutics, TJ Biopharma, AB2 Bio, Novartis, Deepcure, Sobi, Chugai Pharmaceutical, Shionogi, Celltrion, and others |
Key Therapies | ELA026, Plonmarlimab (TJM2/TJ003234), Tadekinig alfa (r-hIL-18BP), MAS825, GAMIFANT, Tocilizumab (Actemra/RoActemra), Tocilizumab biosimilars (Avtozma), and others |
Download the report to understand the latest research on macrophage activation syndrome @ New Macrophage Activation Syndrome Medication - https://www.delveinsight.com/report-store/macrophage-activation-syndrome-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr
Market Insights, Epidemiology, and Forecast — 2034. This report provides a detailed understanding of SLE, including historical and projected epidemiology, individual therapy market shares, and key companies such as Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, and others.
Market Insights, Epidemiology, and Forecast — 2034. This report covers AOSD comprehensively, with epidemiological data, therapy market shares, and profiles of leading companies including Novartis, Swedish Orphan Biovitrum, Roche, Cerecor, AB2 Bio Ltd, and others.
Market Insights, Epidemiology, and Forecast — 2034. This report delivers detailed analysis of JIA, encompassing epidemiological trends, individual therapy market shares, and key companies such as Regeneron, Sanofi, AbbVie, Eli Lilly and Company, Incyte Corporation, Johnson & Johnson, Hope Biosciences, Bristol-Myers Squibb, UCB Biopharma, Novartis, and others.
Market Insights, Epidemiology, and Forecast — 2034. This report provides comprehensive insights into Kawasaki disease, covering epidemiology, therapy market shares, and profiles of key companies including Green Cross Corporation, GC Biopharma Corp, Mitsubishi Tanabe Pharma Corporation, Centocor Inc., Amgen, Takeda, The Emmes Company LLC, and others.
DelveInsight is a premier healthcare-focused market research and consulting firm committed to delivering superior market intelligence and strategic analysis for well-informed business decisions. Backed by a team of seasoned industry specialists with extensive expertise across the life sciences and healthcare sectors, DelveInsight provides customized research solutions and actionable insights to organizations worldwide. Connect with us to access high-quality, accurate, and real-time intelligence that positions you ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: abhishek@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
Athletes often improve faster when they include different types of training in their weekly routine. While football and basketball are different sports, some training methods from basketball can help football players build stronger movement skills.
READ ARTICLEIn recent years, CBD products have gained massive popularity for their potential health benefits, and among them, CBD gummies have become one of the most preferred options. Easy to consume, tasty, and convenient, they offer a simple way to incorporate CBD into daily life. One such trending product in the wellness market is Medibloom CBD Gummies.
READ ARTICLEDiscover how healthcare providers can improve patient engagement, reduce administrative burden, and enhance care through healthcare call center outsourcing.
READ ARTICLE